Abstract: Described herein are methods and devices for monitoring or modulating an immune system in a subject with cancer, and methods and devices for treating a cancer in a subject. The implanted device can electrically stimulate the splenic nerve of the subject, which can modulate the inflammatory system (for example, by increasing or decreasing the blood level of one or more pro-inflammatory cytokines and/or anti-inflammatory cytokines to increase or decrease inflammation in the subject) and/or activate or increase circulation of one or more immune cells (such as natural killer cells and/or cytotoxic T-cells), for the treatment of cancer. The implanted medical device includes two or more electrodes configured to electrically stimulate the splenic nerve, and may further include an ultrasonic transducer configured to receive ultrasonic waves and convert energy from the ultrasonic waves into an electrical energy that powers the device.

Abstract: Method and system embodiments for controlling power provided to a device implantable in a subject are described. In some embodiments, a method is performed at the implantable device to receive, from an interrogator, powering ultrasonic waves having a wave power. Then, energy from the powering ultrasonic waves is converted into an electrical signal to power the implantable device. Information that indicates whether more power or less power should be transmitted to the implantable device is transmitted to the interrogator.

Abstract: Described herein are methods for monitoring or modulating an immune system in a subject; treating, reducing or monitoring inflammation; monitoring blood pressure; treating hypertension; or administering or adjusting a therapy for inflammation or hypertension in a patient by electrically stimulating the splenic nerve or detecting splenic nerve activity using an implanted medical device. Also described herein are implantable medical devices for performing such methods. The implanted medical device includes an ultrasonic transducer configured to receive ultrasonic waves and convert energy from the ultrasonic waves into an electrical energy that powers the device, two or more electrodes in electrical communication with the ultrasonic transducer that are configured to electrically stimulate a splenic nerve or detect a splenic nerve activity, and optionally a splenic nerve attachment member.

Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.

Abstract: Described herein are methods for monitoring or modulating an immune system in a subject; treating, reducing or monitoring inflammation; monitoring blood pressure; treating hypertension; or administering or adjusting a therapy for inflammation or hypertension in a patient by electrically stimulating the splenic nerve or detecting splenic nerve activity using an implanted medical device. Also described herein are implantable medical devices for performing such methods. The implanted medical device includes an ultrasonic transducer configured to receive ultrasonic waves and convert energy from the ultrasonic waves into an electrical energy that powers the device, two or more electrodes in electrical communication with the ultrasonic transducer that are configured to electrically stimulate a splenic nerve or detect a splenic nerve activity, and optionally a splenic nerve attachment member.

Abstract: Described herein is an implantable medical device that includes a body having one or more ultrasonic transducers configured to receive ultrasonic waves and convert energy from the ultrasonic waves into an electrical energy, two or more electrodes in electrical communication with the ultrasonic transducer, and a clip attached to the body that is configured to at least partially surround a nerve and/or a filamentous tissue and position the two or more electrodes in electrical communication with the nerve. In certain examples, the implantable medical device includes two ultrasonic transducers with orthogonal polarization axes. Also described herein are methods for treating incontinence in a subject by converting energy from ultrasonic waves into an electrical energy that powers a full implanted medical device, and electrically stimulating a tibial nerve, a pudendal nerve, or a sacral nerve, or a branch thereof, using the fully implanted medical device.

Abstract: Described herein is an implantable medical device that includes a body having one or more ultrasonic transducers configured to receive ultrasonic waves and convert energy from the ultrasonic waves into an electrical energy, two or more electrodes in electrical communication with the ultrasonic transducer, and a clip attached to the body that is configured to at least partially surround a nerve and/or a filamentous tissue and position the two or more electrodes in electrical communication with the nerve. In certain examples, the implantable medical device includes two ultrasonic transducers with orthogonal polarization axes. Also described herein are methods for treating incontinence in a subject by converting energy from ultrasonic waves into an electrical energy that powers a full implanted medical device, and electrically stimulating a tibial nerve, a pudendal nerve, or a sacral nerve, or a branch thereof, using the fully implanted medical device.

Abstract: An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.

Abstract: An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.

Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.

Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.

Abstract: An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.

Abstract: Compositions and methods are provided that include aggregating microparticles which include an active agent that exhibit an increased hardness and/or durability of the resulting aggregated microparticles in vivo, which can lead to more stable, long-term ocular therapy.

Abstract: Described herein is an implantable medical device that includes a body having one or more ultrasonic transducers configured to receive ultrasonic waves and convert energy from the ultrasonic waves into an electrical energy, two or more electrodes in electrical communication with the ultrasonic transducer, and a clip attached to the body that is configured to at least partially surround a nerve and/or a filamentous tissue and position the two or more electrodes in electrical communication with the nerve. In certain examples, the implantable medical device includes two ultrasonic transducers with orthogonal polarization axes. Also described herein are methods for treating incontinence in a subject by converting energy from ultrasonic waves into an electrical energy that powers a full implanted medical device, and electrically stimulating a tibial nerve, a pudendal nerve, or a sacral nerve, or a branch thereof, using the fully implanted medical device.

Abstract: An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.

Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.

Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.

Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.

Abstract: Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more sustained controlled release of sunitinib or its analog or a pharmaceutically acceptable salt thereof. Increased loading is achieved using an alkaline solvent system. The pharmaceutical compositions can be administered to treat or prevent a disease or disorder in or on the eye of a patient associated with vascularization, such as corneal neovascularization and acute macular degeneration. Upon administration, the sunitinib or its analog or salt is released over an extended period of time at concentrations which are high enough to produce therapeutic benefit, but low enough to avoid unacceptable levels of cytotoxicity.

Abstract: An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.